Regeneron Signs an Agreement with BARDA and the US Department of Defense for REGN-COV2 Worth $450M

 Regeneron Signs an Agreement with BARDA and the US Department of Defense for REGN-COV2 Worth $450M

Regeneron Signs an Agreement with BARDA and the US Department of Defense for REGN-COV2 Worth $450M

Shots:

  • Regeneron and the US Government signed $450M contract for the supply of REGN-COV2 which is currently in two P-II/III clinical trials for the treatment and in a P-III trial for the prevention of COVID-19
  • The collaboration supports continued manufacturing so that the product could be made available immediately in the US if the FDA grants EUA or approval to the therapy. Regeneron will ramp up manufacturing to produce up to 1.6M doses of the cocktail with initial doses to be ready as early as the end of summer
  • Regeneron is evaluating multiple dosages for REGN-COV2 and covers between 70,000 -300,000 treatment doses and 420,000 to 1.3M preventive doses. Regeneron will provide bulk, as well as finished doses of cocktail by the end of 2020

Click here to read full press release/ article | Ref: Regeneron  | Image: Twitter

Related News: Regeneron with its Partner NIAID Report the Initiation of P-III Trial to Evaluate REGN-COV2 for Treatment and Prevention of COVID-19

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post